Europe authorizes application of updated vaccines against Omicron

The European Medicines Agency (EMA), an agency equivalent to Anvisa, authorized, this Thursday (1/9), the application of Pfizer and Moderna vaccines against the Ômicron variant of the coronavirus. The updated formulas will be used in a booster campaign for individuals over 12 years of age who have already completed the vaccination schedule.

According to the regulatory agency, the immunizers “are aimed at the Ômicron BA.1 subvariant, in addition to the original strain”, but do not act directly against the BA.4 and BA.5 strains, which are the predominant variants in the world at the moment. The EMA expects more updated formulas to be approved between late September and December.

Copy of 3 Cards_Gallery_of_Photos (39)

Initially, only the immunocompromised population could receive the second booster dose against Covid-19 in Brazil Reproduction / Brazil Agency

***measles_301119img_29253825

In December 2021, Israel became the first country to announce the application of the fourth dose of the Covid-19 vaccine in the world. According to the government, the reinforcement would help the nation overcome a potential wave of infections by the Ômicron variant.Brazil Agency

Advertising from partner Metrópoles 1

Vaccine syringe color photograph****covid

In early 2022, the country began offering the fourth dose of the Pfizer/BioNtech vaccine to people over 60 and healthcare professionals. Brazil Agency

Vaccination color photograph***Orlando Drummond

According to a study carried out in Israel, the fourth injection in people over 60 years old made them three times more resistant to the coronavirus. Brazil Agency

Metrópoles 2 partner advertising

Vaccination color photograph***vaccination-against-covid-19_51331388769_o_0

Chile and Turkey also started the application of the second booster dose in the population over 60 years of age.Brazil Agency

Vaccination color photograph***vacinacao_drive_thru_universidade_estadual_do_rio_de_janeiro_uerj_tnrgo_abr_2502214597_0

European Union health ministers were instructed in January this year to prepare to distribute the fourth dose of the immunizer as soon as data show it is needed. Brazil Agency

Metrópoles 3 partner advertising

Vaccination color photograph***20210803160416_mg_4218

In Brazil, a technical note from the Ministry of Health, issued in December 2021, recommended that, after four months, the dose should be applied to all immunocompromised individuals, over 18 years of age, who received three doses in the primary regimen.Brazil Agency

Vaccination color photograph***lancamento-vacinacao-gripe_mcamgo_abr_120420211818-8

In May, the Ministry of Health began to recommend the application of the second booster to the elderly aged 60 years and over.Brazil Agency

Metrópoles 4 partner advertising

Vaccination color photograph***Drive-thru vaccination against covid-19 at Parque da Cidade, in Brasília.

On June 20, the recommendation covered the entire population aged 40 and over.Brazil Agency

Hand giving vaccine to the arm of a woman wearing a black strappy blouse****vaccination_contra_a_covid-19_no_parque_da_cidade19062101571_0

Since then, there has been no reduction in the age group.Brazil Agency

Advertising from the Metrópoles 5 partner

Vaccination color photograph***vaccination-against-covid-19_51330864723_o_0

States such as Amazonas, Bahia, Ceará, Rio de Janeiro and São Paulo have reduced the age group on their own and now vaccinate all adults aged 18 and over. Brazil Agency

0

Pfizer and Moderna vaccines against Ômicron have already been approved by the FDA, the regulatory agency of the United States. In Brazil, Anvisa analyzes Pfizer’s request made on August 19.

Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.

Have you read all the Health notes and reports today? Click here.

The article is in Portuguese

Tags: Europe authorizes application updated vaccines Omicron

NEXT Covid-19: Study finds that different comorbidities have different impacts on disease outcomes
-

-

-

-